Bausch Health Companies Inc - BHC STOCK NEWS

Bausch + Lomb, a subsidiary of Bausch Health Companies (NYSE: BHC), will present new scientific data at the ARVO annual meeting from May 1-7, 2021. Highlights include one podium and 11 poster presentations on key products, including the investigational drug XIPERE™ and ongoing ARMOR study on antibiotic resistance. The ARMOR study features insights from 2009-2020 on ocular pathogens, while other presentations will cover recent findings from the pharmaceutical and surgical portfolios. This ongoing commitment to research aims to enhance treatment for eye care professionals.

Bausch Health Companies Inc. (NYSE/TSX: BHC) announced the successful election of 13 nominated directors at its annual meeting on April 27, 2021. Among the elected were Richard U. De Schutter and Sarah B. Kavanagh, receiving over 200 million votes for their positions. Shareholders also approved the compensation of named executive officers in a non-binding advisory vote and appointed PricewaterhouseCoopers LLP as the independent public accounting firm until the 2022 meeting. Full vote details will be reported to the SEC.

Bausch Health Companies Inc. (NYSE/TSX: BHC) has announced the availability of its presentation for the Annual Meeting of Shareholders held on April 27, 2021. This presentation can be accessed via the Investor Relations section of Bausch Health's website. The company focuses on enhancing global health through its diverse healthcare products, including pharmaceuticals and medical devices primarily in eye health, gastroenterology, and dermatology.

Bausch Health Companies (NYSE/TSX: BHC) announced significant topline results from a pivotal Phase 3 trial of IDP-126, a new treatment for acne vulgaris. The trial met all three co-primary endpoints, demonstrating a treatment success rate of 50.5% compared to 20.5% for the vehicle. The study involved 193 participants and showed benefits as early as two weeks. If approved, IDP-126 would be the first-in-class treatment combining retinoid, anti-bacterial, and antibiotic properties. A New Drug Application is anticipated in the second half of 2022.

Bausch Health Companies (NYSE/TSX: BHC) announced six poster presentations at the virtual American Academy of Dermatology (AAD) Annual Meeting, running from April 23-25, 2021. Highlights include new analyses of ARAZLO® (tazarotene) Lotion, focusing on efficacy results from Phase 3 studies for moderate-to-severe acne. Presentations will also cover DUOBRII® (halobetasol propionate and tazarotene) Lotion's effectiveness and quality of life impacts in psoriasis, alongside evaluations of SILIQ® (brodalumab) Injection's long-term efficacy and safety. Scott Hirsch emphasized the commitment to demonstrating clinical benefits.

Bausch Health Companies Inc. announced on April 16, 2021, that its VYZULTA® (latanoprostene bunod ophthalmic solution) has received regulatory approval from ANVISA in Brazil. This marks the tenth approval for VYZULTA, which is indicated for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension. With approvals in ten markets, including the U.S. and several Latin American countries, the company aims to address critical unmet medical needs in glaucoma treatment. Thomas J. Appio emphasized the commitment to further regulatory approvals.

Bausch Health and Novaliq announced successful results from the first Phase 3 trial (GOBI) of NOV03 for treating dry eye disease associated with meibomian gland dysfunction. The trial met both co-primary endpoints, achieving statistical significance in corneal staining and dryness scores at day 15, with continued positive results through day 57. Over 16 million U.S. adults suffer from dry eye disease, making this drug significant. Further studies (MOJAVE and KALAHARI) will assess safety and efficacy, potentially leading to FDA filing in 2022.